Shanghai Henlius Biotech rises most in 5 months on new drug application

Shanghai Henlius Biotech

10/03/2026 03:55

** Shares of Shanghai Henlius Biotech Inc 2696.HK rise 8% to HK$71.25, on track for the biggest one-day pct gain since October 8

** Stock touches the highest point since February 23

** China-based biopharmaceutical group said China's National Medical Products Administration had approved an investigational new drug (IND) application for phase 1 clinical trial of HLX316 for injection in patients with advanced/metastatic solid tumours

** Pre-clinical studies have shown that HLX316 exhibits potent antigen-directed desialylation effects on tumour cells in vitro and potential therapeutic benefit for advanced solid tumors - co

** YTD, stock up 22.2%, Hang Seng Biotech Index .HSBIO up 4%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))